Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics

Liu, Yue; Wang, Jiaqi; Wu, Changxin

doi:10.3389/fnut.2021.626254

Cited by 31 publications

(27 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, research on them has been recently increasing. A growing number of studies have suggested that the microbiota plays an essential role in maintaining normal health, developing the immune system, and providing protection against pathogens (Khan et al, 2016;Dumas et al, 2018;Gupta et al, 2018;Liu et al, 2021). However, the impact of microbiota on host defense against M. tuberculosis infection is poorly understood.…”

Section: Microbiotamentioning

confidence: 99%

Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

Gong

2021

Front. Microbiol.

View full text Add to dashboard Cite

As an ancient infectious disease, tuberculosis (TB) is still the leading cause of death from a single infectious agent worldwide. Latent TB infection (LTBI) has been recognized as the largest source of new TB cases and is one of the biggest obstacles to achieving the aim of the End TB Strategy. The latest data indicate that a considerable percentage of the population with LTBI and the lack of differential diagnosis between LTBI and active TB (aTB) may be potential reasons for the high TB morbidity and mortality in countries with high TB burdens. The tuberculin skin test (TST) has been used to diagnose TB for > 100 years, but it fails to distinguish patients with LTBI from those with aTB and people who have received Bacillus Calmette–Guérin vaccination. To overcome the limitations of TST, several new skin tests and interferon-gamma release assays have been developed, such as the Diaskintest, C-Tb skin test, EC-Test, and T-cell spot of the TB assay, QuantiFERON-TB Gold In-Tube, QuantiFERON-TB Gold-Plus, LIAISON QuantiFERON-TB Gold Plus test, and LIOFeron TB/LTBI. However, these methods cannot distinguish LTBI from aTB. To investigate the reasons why all these methods cannot distinguish LTBI from aTB, we have explained the concept and definition of LTBI and expounded on the immunological mechanism of LTBI in this review. In addition, we have outlined the research status, future directions, and challenges of LTBI differential diagnosis, including novel biomarkers derived from Mycobacterium tuberculosis and hosts, new models and algorithms, omics technologies, and microbiota.

show abstract

Section: Microbiotamentioning

confidence: 99%

Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

Gong

2021

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…To manage drug-resistant tuberculosis, a variety of potential strategies are being proposed, including the use of a pathogen-centric approach of developing new compounds with different mechanisms of action, repurposing drugs, using new analogues of existing anti-tuberculosis drugs, and using host-centric approaches of immunomodulators, therapeutic vaccines, immunity, and cell therapy [ 32 ]. As a form of alternative treatment, probiotics have recently been highlighted for their potential roles in controlling tuberculosis [ 33 ]. In this study, probiotics were applied to develop an alternative approach to solve the problem of antibiotic-resistant M. tuberculosis , and we have reported the anti-tuberculosis effect of P. acidilactici PMC202 isolated from Korean traditional fermented food.…”

Section: Discussionmentioning

confidence: 99%

Anti-Tuberculosis Activity of Pediococcus acidilactici Isolated from Young Radish Kimchi against Mycobacterium tuberculosis

Yoon

Seo

Kim

et al. 2021

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

Tuberculosis is a highly contagious disease caused by Mycobacterium tuberculosis. It affects about 10 million people each year and is still one of the leading causes of death worldwide. About 2 to 3 billion people (equivalent to 1 in 3 people in the world) are infected with latent tuberculosis. Moreover, as the number of multidrug-resistant, extensively drug-resistant, and totally drug-resistant strains of M. tuberculosis continues to increase, there is an urgent need to develop new anti-tuberculosis drugs that are different from existing drugs to combat antibiotic-resistant M. tuberculosis. Against this background, we aimed to develop new anti-tuberculosis drugs using probiotics. Here, we report the anti-tuberculosis effect of Pediococcus acidilactici PMC202 isolated from young radish kimchi, a traditional Korean fermented food. Under coculture conditions, PMC202 inhibited the growth of M. tuberculosis. In addition, PMC202 inhibited the growth of drug-sensitive and -resistant M. tuberculosisinfected macrophages at a concentration that did not show cytotoxicity and showed a synergistic effect with isoniazid. In a 2-week, repeated oral administration toxicity study using mice, PMC202 did not cause weight change or specific clinical symptoms. Furthermore, the results of 16S rRNA-based metagenomics analysis confirmed that dysbiosis was not induced in bronchoalveolar lavage fluid after oral administration of PMC202. The anti-tuberculosis effect of PMC202 was found to be related to the reduction of nitric oxide. Our findings indicate that PMC202 could be used as an anti-tuberculosis drug candidate with the potential to replace current chemicalbased drugs. However, more extensive toxicity, mechanism of action, and animal efficacy studies with clinical trials are needed.

show abstract

“…The beneficial effects of postbiotics in terms of improving health or preventing disease in humans and animals are shown in Table 1 . Moreover, in recent years, postbiotics have been considered a novel approach for cancer treatment as adjuvant therapy and in the treatment of gut-related diseases and infections, such as tuberculosis [ 11 , 12 , 13 , 14 ].…”

Section: The Health Benefit Of Postbiotics and Their Applications In ...mentioning

confidence: 99%

Mineral-Enriched Postbiotics: A New Perspective for Microbial Therapy to Prevent and Treat Gut Dysbiosis

et al. 2022

View full text Add to dashboard Cite

Postbiotics are non-viable probiotic preparations that confer a health benefit on the host. In the last years, scientific literature has proved that postbiotics have health-promoting features and technological advantages compared to probiotics, augmenting their full potential application in the food and pharmaceutical industries. The current work comprehensively summarizes the benefits and potential applications of postbiotics and essential mineral-enriched biomass and proposes a new strategy for microbial therapy—mineral-enriched postbiotics. We hypothesize and critically review the relationship between micronutrients (calcium, magnesium, iron, zinc, selenium) and postbiotics with gut microbiota, which has been barely explored yet, and how the new approach could be involved in the gut microbiome modulation to prevent and treat gut dysbiosis. Additionally, the bioactive molecules and minerals from postbiotics could influence the host mineral status, directly or through gut microbiota, which increases the mineral bioavailability. The review increases our understanding of the health improvements of mineral-enriched postbiotics, including antioxidant functions, highlighting their perspective on microbial therapy to prevent and threaten gut-related diseases.

show abstract

Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics

Cited by 31 publications

References 74 publications

Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

Anti-Tuberculosis Activity of Pediococcus acidilactici Isolated from Young Radish Kimchi against Mycobacterium tuberculosis

Mineral-Enriched Postbiotics: A New Perspective for Microbial Therapy to Prevent and Treat Gut Dysbiosis

Contact Info

Product

Resources

About